Inolimomab is a mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease. Its target is the alpha chain of the interleukin-2 receptor.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD25 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
References
edit- ^ Piñana JL, Valcárcel D, Martino R, Moreno ME, Sureda A, Briones J, et al. (November 2006). "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of Blood and Marrow Transplantation. 12 (11): 1135–1141. doi:10.1016/j.bbmt.2006.06.010. PMID 17085306.
- ^ Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, et al. (2007). "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical Pharmacokinetics. 46 (5): 417–432. doi:10.2165/00003088-200746050-00004. PMC 2760126. PMID 17465640.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |